GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.75
Bid: 14.50
Ask: 15.00
Change: -0.75 (-4.84%)
Spread: 0.50 (3.448%)
Open: 15.00
High: 15.50
Low: 14.75
Prev. Close: 15.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Sale

31 Jan 2007 07:02

Angle PLC31 January 2007 For Immediate Release 31 January 2007 ANGLE plc ('ANGLE' or 'the Company') First Commercial Sale of Synature Product ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce that its Progeny(R)venture company Synature, which offers a new and innovative approach to onlinemarketing, has secured its first commercial sale with a leading player in theworld's most active markets for package holidays and other leisure travelservices. Together they have launched Holiday Matchmaker, a new way for holidaybuyers to find their ideal destination based on recommendations from like-mindedpeople. This is the first commercial sale of Synature's unique patentedtechnology qubox(TM). Holiday Matchmaker utilises Synature's "attitudinal matching" approach todevelop principles derived from constructivist psychology to measure a person'sfeelings on a particular subject - in this case holidays - and thereby connectweb users to relevant content. Feelings are measured in a fun, engaging wayusing Synature's unique proprietary technology qubox(TM), to complete an online'questionnaire'. The results are then processed with state-of-the-art patternrecognition algorithms, derived from research at the University of Cambridge,UK, to provide personalised recommendations. Thousands of users of the customer's website have taken part in a surveyspecifically designed for the launch of the Holiday Matchmaker, which providesrecommendations based entirely on the opinions of an "online jury". The recommendation system uses a scientific measure of like-mindedness to ensurea client's holiday suggestions come from people with compatible views. Thesystem provides suggestions in multiple categories, including "essential picks","dream holidays" and "quirky choices". John Woods, Chief Executive of Synature, commented: "The Holiday Matchmaker is a new way of searching for a travel product. Itsresults are based on the unbiased opinions of a like-minded peer group. Whereasprevious generations of search and personalisation technology have struggledwith complex products such as travel, our approach built on like-mindedness andusing the power of the social internet takes this product complexity in itsstride. We can even tackle hypothetical questions, such as the idea ofrecommending a 'dream holiday'." Andrew Newland, Chief Executive of ANGLE plc, added: "We are delighted that Synature has secured its first commercial sale with aleading player in the holiday market. The Synature qubox(TM)technology has wideapplication in many online markets and we look forward to further developments." For further information ANGLE plc +44 (0)1483 295830Andrew Newland, Chief Executive Synature +44 (0)8701 909550John Woods, Chief Executive Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors: About Synature Synature (www.synature.com) was created by ANGLE in early 2005 to commercialiseintellectual property developed by a Cambridge-based team which offers a newapproach to online target marketing. The company has developed this"attitudinal matching" approach into an ASP service offering advanced socialsearch functionality usable by all types of website including e-commerce, socialnetworks, portals and content sites. About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.